Author: BP Editor
-
Why AstraZeneca Investors Rejected a $400 Billion BMS Megadeal
Reports of a potential $400 billion AstraZeneca–Bristol Myers Squibb combination triggered a sharp market backlash and renewed questions about the value of Big Pharma megamergers.
-
Epicrispr Raises $90 Million to Silence Disease Genes Without Cutting DNA
Epicrispr raised $90 million to advance EPI-321, a single-dose AAV therapy designed to silence DUX4 without permanently editing DNA.
-
Jazz Bets $1.32 Billion on a Precision Therapy for Rare Epilepsy
Jazz is acquiring Actio Biosciences for up to $1.32 billion, gaining ABS-1230, a precision therapy targeting KCNT1-related epilepsy.
-
Moderna Wins FDA Approval for the First mRNA Flu Vaccine
FDA approval of Moderna’s mFlusiva marks the first U.S. approval of an mRNA flu vaccine and expands the platform beyond COVID-19.
-
Tarsus Bets Up to $800 Million on a Deuterated Vitamin A Drug
Tarsus is acquiring Alkeus for up to $800 million, gaining gildeuretinol, a Phase 3 deuterated vitamin A therapy for Stargardt disease.
-
Can Sionna Challenge Vertex’s Cystic Fibrosis Empire?
Sionna’s NBD1-stabilizing therapy could become the first credible challenge to Vertex’s dominant cystic fibrosis franchise.
-
Jazz to Withdraw Zepzelca’s Second-Line SCLC Indication After Phase 3 Failure
Jazz plans to withdraw Zepzelca’s second-line small cell lung cancer indication after the Phase 3 LAGOON trial failed to confirm an overall survival benefit.
-
Curium to Acquire Lantheus in an $8 Billion Radiopharma Deal
Curium’s acquisition of Lantheus could create a global radiopharma leader by combining isotope manufacturing, diagnostics, and commercial scale.
-
AstraZeneca and Bristol Myers Squibb Explore a $400 Billion Pharma Megadeal
AstraZeneca and Bristol Myers Squibb have reportedly explored a potential $400 billion merger. While no deal has been announced, the discussions highlight how U.S. expansion, portfolio diversification and long-term growth are reshaping strategic priorities across the global pharmaceutical industry.
-
Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.